Amryt has expanded its market coverage for Lojuxta with an exclusive distribution agreement for Lebanon, Jordan and Syria, as it got into an agreement with Pharaon Healthcare-Droguerie Mercury S.A.L., one of the leading full-service distributors in the region.
Amryt, a company focused on rare and orphan diseases, estimates that there are about 40 patients with Homozygous Familial Hypercholesterolaemia (HoFH) in the mentioned countries. A therapy to treat adult patients with HoFH, the rare, life-threatening, genetic cholesterol disorder, Lojuxta, could be mostly used in Lebanon in particular, as it is having a pronounced “founder effect” and therefore materially higher prevalence of HoFH.
Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said: “This is Amryt’s fifth new distribution agreement for Lojuxta in approximately three months, and we are delighted to be partnering with Pharaon Healthcare in Lebanon, Jordan and Syria. Pharaon Healthcare has an excellent footprint and many decades of experience in these markets, and this new agreement should help to ensure we can respond effectively to physicians’ requests regarding their patients suffering with HoFH.“